Cargando…

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor

Prostate cancer is the most commonly diagnosed and second-most lethal cancer among men in the United States. The vast majority of prostate cancer deaths are due to castration-resistant prostate cancer (CRPC) – the lethal form of the disease that has progressed despite therapies that interfere with a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coleman, Daniel J., Van Hook, Kathryn, King, Carly J., Schwartzman, Jacob, Lisac, Robert, Urrutia, Joshua, Sehrawat, Archana, Woodward, Josha, Wang, Nicholas J., Gulati, Roman, Thomas, George V., Beer, Tomasz M., Gleave, Martin, Korkola, James E., Gao, Lina, Heiser, Laura M., Alumkal, Joshi J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130036/ https://www.ncbi.nlm.nih.gov/pubmed/27276681 http://dx.doi.org/10.18632/oncotarget.9816

Ejemplares similares

Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer
por: King, Carly J., et al.
Publicado: (2017)

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
por: Alumkal, Joshi J., et al.
Publicado: (2020)

Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
por: Gao, Lina, et al.
Publicado: (2013)

Enzalutamide: the emperor of all anti-androgens
por: Antonarakis, Emmanuel S.
Publicado: (2013)

Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
por: Smith, Rebecca, et al.
Publicado: (2020)

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
por: Cochrane, Dawn R, et al.
Publicado: (2014)

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
por: Coleman, Daniel J., et al.
Publicado: (2019)

Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer
por: Ware, Kathryn E., et al.
Publicado: (2016)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

Biomarkers of Castrate Resistance in Prostate Cancer: Androgen Receptor Amplification and T877A Mutation Detection by Multiplex Droplet Digital PCR
por: Young, Francis P., et al.
Publicado: (2022)

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
por: Xu, Pengfei, et al.
Publicado: (2023)

Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells
por: Terakawa, T, et al.
Publicado: (2009)

Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide
por: Hong, Zhe, et al.
Publicado: (2021)

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants
por: Shiota, Masaki, et al.
Publicado: (2018)

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
por: Hoefer, Julia, et al.
Publicado: (2016)

Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens
por: Ito, Yusuke, et al.
Publicado: (2018)

Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance
por: Nicolescu, Radu Costin Bizga, et al.
Publicado: (2022)

Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
por: Salami, Jemilat, et al.
Publicado: (2018)

Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants
por: Banuelos, Carmen A., et al.
Publicado: (2020)

Androgens and Androgen Receptor Actions on Bone Health and Disease: From Androgen Deficiency to Androgen Therapy
por: Chen, Jia-Feng, et al.
Publicado: (2019)

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
por: Graff, Julie N, et al.
Publicado: (2020)

Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer
por: Zhao, Jingwen, et al.
Publicado: (2016)

The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression()
por: Li, Zhenghong, et al.
Publicado: (2020)

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
por: Wardley, Andrew, et al.
Publicado: (2021)

Androgen Receptor Blockade Using Enzalutamide Suppresses Long Non-Coding RNA ARLNC1 in Prostate Cancer Cells
por: Huseynova, Günel, et al.
Publicado: (2022)

Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells
por: Choupani, Edris, et al.
Publicado: (2022)

Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications
por: Dong, Xin, et al.
Publicado: (2022)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Androgen regulation of the androgen receptor coregulators
por: Urbanucci, Alfonso, et al.
Publicado: (2008)

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer
por: Chou, Fu-Ju, et al.
Publicado: (2020)

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
por: Graff, Julie N., et al.
Publicado: (2016)

Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)

Enzalutamide induced non-ischemic cardiomyopathy. A case report and review of literature on anti-androgen therapy-related cardiovascular events
por: Kumar, Aswini, et al.
Publicado: (2023)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
por: You, Xiangyun, et al.
Publicado: (2023)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study
por: Iguchi, Taro, et al.
Publicado: (2021)

Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling
por: Lin, T-H, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rcth2br4mcf0nkv4u9pbem8q1p